Andere talen Pharma Mar, S.A.

Aandelen

PHM

ES0169501022

Geschatte realtime Tradegate Andere beurzen 13:56:16 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
27,4 ^EUR	+3,32%		+3,92%	-32,86%

29/02	Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
28/02	Pharma Mar, S.A. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

EN DIRECTO DESDE LOS MERCADOS: Naturgy, Viscofan, Endesa, Bankinter, Aena, BYD, TotalEnergies, Tesla, UBS, Salesforce, Nike...	22/04
IN DIRETTA DAI MERCATI: Generali, Viscofan, Telecom Italia, Iveco, Henkel, BYD, TotalEnergies, Tesla, UBS, Salesforce, Nike...	22/04
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
OPINIONES DE LOS ANALISTAS DEL DÍA : Adyen, Endesa, Viscofan, Iberdrola, Repsol, Pharma Mar, NH Hotel, Nemetschek, Société Générale...	09/02
Bolsa de Madrid: Caramba, ¡falló otra vez!	09/02
PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers	30/01
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Repsol, Cie Automotive, Alphabet, UBS, Acciona, Richemont, Covestro, Apple...	19/12
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication	18/12
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12/12
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05/12
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	04/12
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru	07/11
PharmaMar receives a payment of 10 million dollars from Janssen as a commercial milestone	07/11
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal	06/11
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Sacyr, LVMH, Iberdrola, Dufry, Berkshire Hathaway, Ryanair, Telecom Italia	06/11
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	26-10-23
PharmaMar presents new data on lurbinectedin for small cell lung cancer at ESMO 2023	19-10-23
OPINIONES DE LOS ANALISTAS DEL DÍA : Amadeus, Sacyr, Nokia, Telefónica, Pharma Mar, Novo Nordisk, Rheinmetall, Prosegur, Almirall, Vodafone...	11-10-23
PharmaMar increased investment in R&D in oncology by 23% in 2022	25-09-23
PharmaMar licenses lurbinectedin to Key Oncologics for marketing and distribution in Africa	13-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pharma Mar, S.A.

Aandelen

PHM

ES0169501022

Andere talen

Filters